Positive Outlook on Nuvation Bio’s Safusidenib Driven by Promising Clinical Data and Strategic Focus
I'm PortAI, I can summarize articles.
JonesTrading analyst Soumit Roy maintains a Buy rating on Nuvation Bio (NUVB) stock, driven by promising clinical data and strategic focus on safusidenib, an IDH1 inhibitor. Recent Phase 2 trial data from Daiichi Sankyo shows a 44% response rate and 88% progression-free survival at 24 months. Nuvation Bio's alignment with the FDA and focus on unmet medical needs, along with strong financials, support this positive outlook. H.C. Wainwright also reiterates a Buy rating with a $10 price target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments